www.hiv-druginteractions.org

LIVERPOOL

Report ID: Date Produced: 21 April 2025

Antiretroviral Treatment	Co-medications
Efavirenz (EFV)	Ciprofloxacin

**Interaction Report** 

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.hiv-druginteractions.org .

## Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

## Efavirenz (EFV) + Ciprofloxacin

Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged by the kidneys by glomerular filtration and tubular secretion via OAT3. It is also metabolized and partially cleared through the bile and intestine. Ciprofloxacin has a known risk of QT prolongation and/or TdP on the CredibleMeds.org website. Efavirenz was shown to prolong the QT interval above the regulatory threshold of concern in homozygous carriers of the CYP2B6\*6/\*6 allele (i.e. 516T variant in the gene encoding CYP2B6). The European product label for efavirenz contraindicates coadministration with a drug with a known risk of Torsade de Pointes whereas the American product label for efavirenz recommends that alternatives should be considered. As the potential risk of a QT interval prolongation relates specifically to homozygous carriers of CYP2B6\*6/\*6 and given the accumulated years of safety data with efavirenz and such drugs, the contraindication is not reflected in the colour coding of this interaction summary.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

This report is provided for information only. It is not intended to replace a consultation with an appropriately qualified beats protestional. Information presented relates only to know our subjected effects of interacting medications, and is based on relevant data in the public domain. No clinical advice is given or implied, clinicians must exercise their own judgement in relation to the risks and benefits of combining drugs, which depend on factors beyond pharmacokinetic interactions between two drugs. The University of Liverpool and not be held responsible for the application or use of any information risks are affected in any weighted by the service that income and the user shall hold the University of Liverpool and interactions against any consequences arising from negligence or of nany explicible for the continued currency of information in this publication whether arising from negligence or of nany consequences arising